Management's Discussion:
"Today we are reporting 2025 net operating income of $1.6 million, an increase of $3.3 million compared to 2024. These results were largely driven by a significant improvement in gross margin, reflecting higher volumes, manufacturing efficiencies, and price realization," commented Timothy C. Fiori, Chief Financial Officer of ImmuCell. "Net loss for 2025 was $1.0 million, an improvement of $1.1 million compared to 2024. As previously discussed, we saw several non-recurring items in 2025 that affected our net loss, including a $2.7 million write-down of Re-Tain® assets, $651,000 of colostrum inventory write-downs, and $297,000 of expenses related to CEO transition, partially offset by $427,000 of one-time income from insurance proceeds received."
"2025 was a successful year for ImmuCell," said Olivier te Boekhorst, President and CEO of ImmuCell. "As first announced on January 8, 2026, revenue in 2025 grew by 4.3% compared to 2024 as our commercial team stepped up customer outreach. Our manufacturing team contributed by increasing average monthly output from approximately 345,000 units per month in 2024 to 380,000 units per month in 2025. In December, the Company also announced a new strategy of focusing on our successful on-market First Defense® franchise. Looking forward, we are expecting to see positive results from our investments in commercial expansion and continued manufacturing yield improvement efforts," continued Mr. te Boekhorst.
Certain Financial Results:
2025 product sales increased 4.3% to approximately $27.6 million compared to the year ended December 31, 2024.
2025 gross profit improved to 41.4% of product sales during the year ended December 31, 2025 compared to 30% during the year ended December 31, 2024.
Net loss was $1.0 million, or ($0.12) per basic share, during the year ended December 31, 2025 compared to a net loss of $2.2 million, or ($0.26) per basic share, during the year ended December 31, 2024.
Balance Sheet Data as of December 31, 2025:
Cash and cash equivalents remained at $3.8 million as of December 31, 2025 and 2024, with no draw outstanding on the available $1 million line of credit as of either date.
Net working capital increased to approximately $13.0 million as of December 31, 2025 from $10.6 million as of December 31, 2024, due primarily to an increase in finished goods inventory.
Stockholders' equity decreased to $27.1 million as of December 31, 2025 from $27.5 million as of December 31, 2024.
Condensed Statements of Operations (Unaudited)
During the Three-Month
During the Years Ended
Periods Ended December 31,
December 31,
(In thousands, except per share amounts)
2025
2024
2025
2024
Product sales
$7,626
$7,751
$27,644
$26,493
Costs of goods sold
4,716
4,919
16,199
18,552
Gross profit
2,910
2,832
11,445
7,941
Product development expenses
759
819
3,042
3,899
Sales, marketing and administrative expenses
2,209
1,391
6,754
5,682
Operating expenses
2,968
2,210
9,796
9,581
NET OPERATING (LOSS) INCOME
(58
)
622
1,649
(1,640
)
